Drug intelligence / Profile preview

AAV8-TBGp-Cre

Development stage: Preclinical
Lead developer: University of Illinois Chicago
Modality: Gene Therapies
Administration: Intravenous

Overview

AAV8-TBGp-Cre is an adeno-associated virus serotype 8 (AAV8) gene therapy vector designed for hepatocyte-specific expression of Cre recombinase. It utilizes the liver-specific thyroxine-binding globulin (TBG) promoter to drive the expression of Cre, which allows for the conditional deletion of genes flanked by loxP sites (floxed) specifically in the liver. In research settings, it is frequently used to generate adult-onset, hepatocyte-specific knockout models to study liver metabolism and the progression of metabolic dysfunction-associated steatohepatitis (MASH). The AAV8 capsid provides high tropism for hepatocytes, ensuring efficient delivery and localized action within the liver upon systemic administration.

Other names: AAV8-TBG-CreAAV-8-TBG-CreAAV 8-TBG-Cre

Targets

DNA

Beyond the preview

Go deeper on AAV8-TBGp-Cre.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV8-TBGp-Cre.

Explore the full profile